# A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

> **NCT02861534** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5050 (actual)

## Conditions studied

- Heart Failure
- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Vericiguat
- **DRUG:** Placebo for vericiguat

## Key facts

- **NCT ID:** NCT02861534
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2019-06-18
- **Final completion:** 2019-09-02
- **Target enrollment:** 5050 (ACTUAL)
- **Last updated:** 2021-11-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02861534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02861534, "A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02861534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*